{"analyses":[{"ciLowerLimit":"0.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.43","estimateComment":"A smaller ratio represents larger benefit.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Rate ratio","paramValue":"0.28","statisticalMethod":"Negative Binomial Model, Adjusted"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.2","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"1.5","value":"0.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"description":"Rate of RBC transfusion was defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the double-blind phase.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received momelotinib plus placebo to match ruxolitinib.\n\nMomelotinib tablets were administered orally once daily at a starting dose of 200 mg.\n\nAdditional available strengths included 100 mg and 150 mg. Placebo to match ruxolitinib tablets were administered orally twice daily.","id":"OG000","title":"Momelotinib (MMB)"},{"description":"Participants received ruxolitinib plus placebo to match momelotinib.\n\nRuxolitinib tablets were administered orally twice daily. The dose ranged from 5 to 20 mg BID and was dependent on platelet count, creatinine clearance, and transaminase levels.\n\nPlacebo to match momelotinib tablets were administered orally once daily.","id":"OG001","title":"Ruxolitinib (RUX)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline to Week 24","title":"Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)","type":"SECONDARY","unitOfMeasure":"units/month"}